Rechipharm contracted to make lidocaine formulation for IUD-related pain

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Initial public offering

Rechipharm contracted to make novel lidocaine formulation
Recipharm AB will manufacture commercial supplies of a topical formulation of the anaesthetic lidocaine called Shact that is soon to be launched by developer Pharmanest AB.

The new contract –terms of which were not disclosed – will see the Swedish contract manufacturing organisation’s (CMO) semi-solid products unit make Shact – which is used to alleviate discomfort and pain during IUD insertion - at its facility in Karlskoga.

Recipharm will manufacture Shact along with a proprietary application device developed to simplify topical application in the cervix and uterus in a long term deal that will extend to any country in which the drug is launched.

The manufacturing contract is the first Recipharm has announced since it completed its initial public offering on the NASDAQOMX exchange on April 3.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Related suppliers

Follow us


View more